A citation-based method for searching scientific literature

B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh, D B Rawlins, N C Goodwin, R Mabon, B A Harrison, A Wilson, A Sands, D R Powell. Clin. Pharmacol. Ther. 2012
Times Cited: 137



Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol. Rev. 2011
Times Cited: 560




List of shared articles



Times cited

SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar. Fundam Clin Pharmacol 2020
1

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J. Clin. Endocrinol. Metab. 2020
0

Sodium-glucose cotransporters: Functional properties and pharmaceutical potential.
Ryuhei Sano, Yuichi Shinozaki, Takeshi Ohta. J Diabetes Investig 2020
1

Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
0



A Modified Tripeptide Motif of RS1 (RSC1A1) Down-Regulates Exocytotic Pathways of Human Na+-d-glucose Cotransporters SGLT1, SGLT2, and Glucose Sensor SGLT3 in the Presence of Glucose.
Nadine Schäfer, Prashanth Reddy Rikkala, Maike Veyhl-Wichmann, Thorsten Keller, Christian Ferdinand Jurowich, Dietmar Geiger, Hermann Koepsell. Mol. Pharmacol. 2019
1

Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo.
Kyu Hang Lee, Sang Don Lee, Namdu Kim, Kwee Hyun Suh, Young Hoon Kim, Sang Soo Sim.  2019
1

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
16

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
18

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
5

Ion channels and transporters in diabetic kidney disease.
Denisha Spires, Anna D Manis, Alexander Staruschenko. Curr Top Membr 2019
5


SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
9



Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet.
Markus Mühlemann, Daniela Zdzieblo, Alexandra Friedrich, Constantin Berger, Christoph Otto, Heike Walles, Hermann Koepsell, Marco Metzger. Mol Metab 2018
3

RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury.
Anne Sebastiani, Frederik Greve, Christina Gölz, Carola Y Förster, Hermann Koepsell, Serge C Thal. J. Neurochem. 2018
3

Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
42


Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu. Expert Opin Drug Metab Toxicol 2017
8

LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice.
David R Powell, Melinda G Smith, Deon D Doree, Angela L Harris, Jennifer Greer, Christopher M DaCosta, Andrea Thompson, Sabrina Jeter-Jones, Wendy Xiong, Kenneth G Carson,[...]. J. Pharmacol. Exp. Ther. 2017
11



Duodenal Sodium/Glucose Cotransporter 1 Expression Under Fasting Conditions Is Associated With Postload Hyperglycemia.
Teresa Vanessa Fiorentino, Evelina Suraci, Gaetano Paride Arcidiacono, Antonio Cimellaro, Chiara Mignogna, Ivan Presta, Francesco Andreozzi, Marta Letizia Hribal, Francesco Perticone, Giuseppe Donato,[...]. J. Clin. Endocrinol. Metab. 2017
9

SGLT2 inhibitors.
I Dardi, T Kouvatsos, S A Jabbour. Biochem. Pharmacol. 2016
11

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Elza Muscelli, Brenno Astiarraga, Elisabetta Barsotti, Andrea Mari, Freimut Schliess, Leszek Nosek, Tim Heise, Uli C Broedl, Hans-Juergen Woerle, Ele Ferrannini. Diabetologia 2016
9

Bile Diversion in Roux-en-Y Gastric Bypass Modulates Sodium-Dependent Glucose Intestinal Uptake.
Gregory Baud, Mehdi Daoudi, Thomas Hubert, Violeta Raverdy, Marie Pigeyre, Erik Hervieux, Magalie Devienne, Mohamed Ghunaim, Caroline Bonner, Audrey Quenon,[...]. Cell Metab. 2016
40

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Panai Song, Akira Onishi, Hermann Koepsell, Volker Vallon. Expert Opin. Ther. Targets 2016
50

Sodium glucose transport modulation in type 2 diabetes and gastric bypass surgery.
Gregory Baud, Violeta Raverdy, Caroline Bonner, Mehdi Daoudi, Robert Caiazzo, François Pattou. Surg Obes Relat Dis 2016
7

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
Julio Rosenstock, William T Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks, Arthur Sands. Diabetes Care 2015
41

Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
Ivana Vrhovac, Daniela Balen Eror, Dirk Klessen, Christa Burger, Davorka Breljak, Ognjen Kraus, Nikola Radović, Stipe Jadrijević, Ivan Aleksic, Thorsten Walles,[...]. Pflugers Arch. 2015
105


Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Linda A Gallo, Ernest M Wright, Volker Vallon. Diab Vasc Dis Res 2015
120

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
50



LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.
David R Powell, Melinda G Smith, Deon D Doree, Angela L Harris, Wendy W Xiong, Faika Mseeh, Alan Wilson, Suma Gopinathan, Damaris Diaz, Nicole C Goodwin,[...]. Pharmacol Res Perspect 2015
7

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
100

Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Bertrand Cariou, Bernard Charbonnel. Expert Opin Investig Drugs 2015
18

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.
Sunder Mudaliar, David Polidori, Brian Zambrowicz, Robert R Henry. Diabetes Care 2015
97